The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | KEYNOTE-937: adjuvant pembro for pts with HCC after surgical resection/local ablation
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, discusses findings from the KEYNOTE-937 study (NCT03867084), which evaluated adjuvant pembrolizumab for participants with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation. Adjuvant pembrolizumab versus placebo did not demonstrate improvement in relapse-free survival in patients with HCC after surgical resection or local ablation. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
